Halobetasol Propionate; Tazarotene Patent Expiration
Halobetasol Propionate; Tazarotene is Used for treating plaque psoriasis in adults. It was first introduced by Bausch Health Americas Inc
Halobetasol Propionate; Tazarotene Patents
Given below is the list of patents protecting Halobetasol Propionate; Tazarotene, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Duobrii | US10251895 | Topical compositions and methods for treating psoriasis | Jun 06, 2036 | Bausch |
| Duobrii | US10426787 | Topical compositions and methods for treating psoriasis | Jun 06, 2036 | Bausch |
| Duobrii | US10478502 | Pharmaceutical formulations containing corticosteroids for topical administration | Nov 02, 2031 | Bausch |
| Duobrii | US11648256 | Topical compositions and methods for treating psoriasis | Jun 06, 2036 | Bausch |
| Duobrii | US11679115 | Topical compositions and methods for treating psoriasis | Jun 06, 2036 | Bausch |
| Duobrii | US11839656 | Pharmaceutical formulations containing corticosteroids for topical administration | Nov 02, 2031 | Bausch |
| Duobrii | US11957753 | Pharmaceutical formulations containing corticosteroids for topical administration | Nov 02, 2031 | Bausch |
| Duobrii | US11986527 | Pharmaceutical formulations containing corticosteroids for topical administration | Nov 02, 2031 | Bausch |
| Duobrii | US6517847 | Topical gel delivery system |
Aug 03, 2020
(Expired) | Bausch |
| Duobrii | US8809307 | Pharmaceutical formulations containing corticosteroids for topical administration | Nov 02, 2031 | Bausch |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳